Analysts Offer Predictions for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Caribou Biosciences in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of $16.92 per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

A number of other equities analysts have also recently commented on the stock. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup cut their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Caribou Biosciences has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Trading Down 8.0 %

CRBU stock opened at $1.72 on Wednesday. Caribou Biosciences has a 1-year low of $1.50 and a 1-year high of $8.33. The business’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $2.00. The firm has a market capitalization of $155.75 million, a PE ratio of -1.04 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CRBU. Renaissance Technologies LLC bought a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $2,432,000. Dimensional Fund Advisors LP raised its holdings in Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after acquiring an additional 536,162 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Caribou Biosciences by 103.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 82,494 shares of the company’s stock worth $162,000 after purchasing an additional 41,948 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.